Dronedarone in high-risk permanent atrial fibrillation.
(2011) New England Journal of Medicine — Vol. 365, n° 24, p. 2268-2276 (2011)
Files
ConnollySJ-NEJM2012.pdf
Restricted Access - Adobe PDF
- 644.03 KB
Details
- Authors
- Abstract
- Dronedarone increased rates of heart failure, stroke, and death from cardiovascular causes in patients with permanent atrial fibrillation who were at risk for major vascular events. Our data show that this drug should not be used in such patients. (Funded by Sanofi-Aventis; PALLAS ClinicalTrials.gov number, NCT01151137.).
- Affiliations
Citations
Connolly, S. J., Camm, A. J., Halperin, J. L., Joyner, C., Alings, M., Amerena, J., Atar, D., Avezum, Á., Blomström, P., Borggrefe, M., Budaj, A., Chen, S.-A., Ching, C. K., Commerford, P., Dans, A., Davy, J.-M., Delacrétaz, E., Di Pasquale, G., Diaz, R., et al. (2011). Dronedarone in high-risk permanent atrial fibrillation. New England Journal of Medicine, 365(24), 2268-2276. https://doi.org/10.1056/NEJMoa1109867 (Original work published 2011)